Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis
Authors' conclusion
Despite clinical concerns raised by ORAL Surveillance, our findings indicate no direct enhancement of platelet reactivity by TOFA. Instead, TOFA attenuated IL-6-driven TF expression in endothelial cells, pointing to a possible protective effect on vascular thrombogenic pathways.
Study context
- Population
- Healthy volunteers, rheumatoid arthritis (RA) patients on tofacitinib (TOFA) and human umbilical vein endothelial cells (HUVECs)
- Comparison
- TOFA vs no TOFA on platelet aggregation and IL-6-induced endothelial tissue factor (TF)
- Healthy volunteersn = 12
- RAn = 14
- Outcome
- Effects of TOFA on platelet aggregation and TF-mediated coagulation pathways
Methodological detailsin vitro, ex vivo
- In vitro
- Ex vivo
Main finding
As reported in the abstract
- TOFA did not alter ADP-induced platelet aggregation ex vivo in either healthy volunteers or RA patients
- TOFA significantly reduced IL-6-induced TF mRNA expression and activity in HUVECs
Original publication
Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →